EcoDrugPlus

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSATEG00000015926
Gene Symbol: CACNG7A
3 Cross references
188 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7b

Ensembl ID : ENSATEG00000022380
Gene Symbol: CACNG7B
2 Cross references
190 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8a

Ensembl ID : ENSATEG00000029552
Gene Symbol: CACNG8A
1 Cross references
170 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSATEG00000001953
Gene Symbol: CACNA2D1
1 Cross references
229 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSATEG00000023582
Gene Symbol: CACNA2D3
1 Cross references
216 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSATEG00000014886
Gene Symbol: CACNA2D4
3 Cross references
234 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSATEG00000004521
Gene Symbol: CACNB2
3 Cross references
204 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSATEG00000003524
Gene Symbol: CACNB4
3 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 1

Ensembl ID : ENSATEG00000028136
Gene Symbol: CACNG1
3 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 4

Ensembl ID : ENSATEG00000007147
Gene Symbol: CACNG4
1 Cross references
189 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSATEG00000007126
Gene Symbol: CACNG5
3 Cross references
184 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSATEG00000025694
Gene Symbol: CACNG8
3 Cross references
163 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).